tiotropium bromide 18mcg

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

CompletedNCT01627327

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2012-04-01End: 2012-12-21Updated: 2017-11-09

Phase 4

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

CompletedNCT00361959

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2003-06-30End: 2006-02-28Updated: 2017-01-20

Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

CompletedNCT01762800

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2013-02-28End: 2015-09-30Updated: 2016-11-10

Related Papers

LATE-BREAKING ABSTRACT: Large differences in rate of reported and unreported COPD exacerbations in Japanese patients; data from the COSMOS-J trial

2016-09-01

A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011.

2013-10-038 citations

Reported pneumonia in patients with COPD: findings from the INSPIRE study.

2010-06-24114 citations